VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein.
about
Therapies targeting cancer stem cells: Current trends and future challengesMutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.Glycolysis inhibition inactivates ABC transporters to restore drug sensitivity in malignant cellsSynthesis of a dual functional anti-MDR tumor agent PH II-7 with elucidations of anti-tumor effects and mechanismsThe FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactionsTargeting multidrug resistance in cancerVascular colocalization of P-glycoprotein, multidrug-resistance associated protein 1, breast cancer resistance protein and major vault protein in human epileptogenic pathologies.A high-throughput cell-based assay for inhibitors of ABCG2 activity.Epigenetic mechanisms involved in differential MDR1 mRNA expression between gastric and colon cancer cell lines and rationales for clinical chemotherapyCurrent Advances in Developing Inhibitors of Bacterial Multidrug Efflux PumpsPrevention of multidrug resistance (MDR) in osteosarcoma by NSC23925.The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance.ABC multidrug transporters: structure, function and role in chemoresistance.Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fieldsSildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update.The challenge of exploiting ABCG2 in the clinic.ABCG2: a perspective.ABC transporters: unvalidated therapeutic targets in cancer and the CNSP-glycoprotein antagonists confer synergistic sensitivity to short-chain ceramide in human multidrug-resistant cancer cells.Stereoselective Modulation of P-Glycoprotein by Chiral Small Molecules.PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanismImproving cancer chemotherapy with modulators of ABC drug transporters.Chamaejasmin B exerts anti-MDR effect in vitro and in vivo via initiating mitochondria-dependant intrinsic apoptosis pathway.Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2.Role of the breast cancer resistance protein (ABCG2) in drug transport.Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins.Breast cancer resistance protein in pharmacokinetics and drug-drug interactions.Salubrinal-Mediated Upregulation of eIF2α Phosphorylation Increases Doxorubicin Sensitivity in MCF-7/ADR Cells.Understanding and targeting cancer stem cells: therapeutic implications and challenges.The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies.Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges.The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanismsIdentification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute Anticancer Drug Screen.The Role of Eukaryotic and Prokaryotic ABC Transporter Family in Failure of Chemotherapy.The controversial role of ABC transporters in clinical oncology.Recent trends in cancer drug resistance reversal strategies using nanoparticles.Human ABCG2: structure, function, and its role in multidrug resistance.
P2860
Q26777880-E581A385-04F1-4D13-8D5C-0D0BC68D6330Q27851423-CABC3798-B5EF-42CD-8AED-694117B98D78Q28477764-EAE09ADC-0B59-4CE1-B57F-94E54B197C35Q28481389-3E07C0F0-BF50-48E0-AA81-7090BE5A3091Q28535342-903534A1-4186-43D8-8B3C-F11CF90D2CD3Q29616803-4FE6F2BC-B0F9-498A-B1AD-A36597419F2BQ33231530-4B36C208-DC1E-40A4-B12A-DE1879AA813DQ33234390-C238291B-D281-4674-8878-80F479AF9B0DQ33357010-009B3C73-3890-4B2E-87A5-2D44AB2B9212Q33659230-1F696E9D-CE0B-415D-9592-4B59EB5D6FA5Q33750171-581B5D39-D6E3-4BF4-B938-D589FF65722BQ33753716-52A86636-9728-481A-925B-CF05C2B71879Q34586418-C527D079-4E75-4F24-903E-7225BD0A50D1Q34743441-80593968-B5BC-4354-884B-02BA50D4C75AQ34754007-7252B35E-F790-4CC3-A7D8-512C4139779CQ34803651-446B194E-C6F6-4244-B0A0-E3C955FCA042Q34871636-C50882F0-BF6B-4A0B-B9B9-3BC1FA6751F2Q34968909-8ED924F3-619B-48EC-B79E-535DD2A706A7Q35016817-011DE1C6-7360-4578-B697-23FE2B9AE9ADQ35056738-E3F2BF45-CBAC-476B-A5EC-18E71A3D1242Q35057879-7048DA1C-D2AF-41AB-9DFE-3D2740436C7BQ35836745-3DC22A07-61A1-4657-B434-66E1F97006BFQ35847659-85244D5D-9227-4EF0-BD06-6959B3F19861Q36108251-5499B9C0-D229-41BA-8676-9D81B51CBC56Q36111203-3A5F96B2-776C-4C6D-AA92-6792D4355977Q36120816-46A1FB9C-28E1-435F-94A1-ABE8181095A3Q36250753-7890EB4C-57B3-458C-823F-A236F3087B76Q36525551-482CD0A8-199B-4652-8D3E-C08815CD9716Q36544862-72C82D99-AC19-4A2D-B433-90C10DADAA36Q36591295-6171DCE7-64EC-489A-8FF7-4325A24553BFQ36907405-1C2081ED-C443-4D40-AFEF-67DB81E8207EQ36933169-749D2C60-6FDD-40A6-8569-FC64B54DE501Q37010772-92DD7A20-7B00-4E20-92E3-A4B007A62DD9Q37076348-29B49A0C-D07F-4D19-AA28-627B44BB3E51Q37289700-798AE18C-32CD-4BE8-BC3E-CF417276C3ECQ37415822-87D80360-A027-477C-AB93-33996B408311Q37576360-157DAF5F-1C73-494A-93A7-6D4A4C67F854Q37941758-61E35C5D-1FCC-4FD3-B32D-DB077D0F0EC3Q37984588-8B618500-0467-412A-B4A9-0C92A52097EFQ38003156-25828527-429D-475B-AC60-837AF246C536
P2860
VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein.
description
2004 nî lūn-bûn
@nan
2004 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մարտին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
VX-710 (biricodar) increases d ...... ast cancer resistance protein.
@ast
VX-710 (biricodar) increases d ...... ast cancer resistance protein.
@en
VX-710 (biricodar) increases d ...... ast cancer resistance protein.
@nl
type
label
VX-710 (biricodar) increases d ...... ast cancer resistance protein.
@ast
VX-710 (biricodar) increases d ...... ast cancer resistance protein.
@en
VX-710 (biricodar) increases d ...... ast cancer resistance protein.
@nl
prefLabel
VX-710 (biricodar) increases d ...... ast cancer resistance protein.
@ast
VX-710 (biricodar) increases d ...... ast cancer resistance protein.
@en
VX-710 (biricodar) increases d ...... ast cancer resistance protein.
@nl
P2093
P1476
VX-710 (biricodar) increases d ...... ast cancer resistance protein.
@en
P2093
Hans Minderman
Kieran L O'Loughlin
Lakshmi Pendyala
Maria R Baer
P304
P356
10.1158/1078-0432.CCR-0914-3
P407
P577
2004-03-01T00:00:00Z